Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 7, 2020 7:31 AM EDTPhase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020
AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies by the end of 2020
Actively screening multiple new molecular entities in recently initiated COVID-19 research program
Cash runway guidance extended into mid-2022
Conference Call and Webcast Scheduled Today at 8:45 AM ET
... More